ScholarIQanswers from OpenAlex
Instituto Oncológico Dr. Rosell
InstitutionResearch output, impact & collaborations
Instituto Oncológico Dr. Rosell is a institution indexed in ScholarIQ from OpenAlex.
What is known about Instituto Oncológico Dr. Rosell?
ScholarIQrecord summary
Instituto Oncológico Dr. Rosell is a research organisation in Barcelona, ES. OpenAlex records 854 works and 57,496 citations for it. 153 researchers list it as their most recent affiliation.
How many works does Instituto Oncológico Dr. Rosell have?
ScholarIQindexed works
Instituto Oncológico Dr. Rosell has 854 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Instituto Oncológico Dr. Rosell have?
ScholarIQcitation count
Instituto Oncológico Dr. Rosell has 57,496 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Instituto Oncológico Dr. Rosell?
ScholarIQresearcher count
Instituto Oncológico Dr. Rosell has 153 researchers in the ScholarIQ index.
What is the average h-index at Instituto Oncológico Dr. Rosell?
ScholarIQavg h-index
Instituto Oncológico Dr. Rosell has an average h-index of 94 in OpenAlex.
What is the ROR of Instituto Oncológico Dr. Rosell?
ScholarIQror
The ROR for Instituto Oncológico Dr. Rosell is on the source record.
What is the OpenAlex record for Instituto Oncológico Dr. Rosell?
ScholarIQopenalex
The OpenAlex for Instituto Oncológico Dr. Rosell is on the source record.
Who are the most-cited researchers behind Instituto Oncológico Dr. Rosell?
ScholarIQtop researchers by citations
What are the most-cited papers on Instituto Oncológico Dr. Rosell?
ScholarIQmost cited works
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
Jean‐Pierre Pignon, Hélène Tribodet, Giorgio V. Scagliotti, Jean-Yves Douillard, Frances A. Shepherd, Richard Stephens, Ariane Dunant, Valter Torri, Rafael Rosell, Lesley Seymour, Stephen Spiro, Estelle Rolland, Roldano Fossati, D. Aubert, Keyue Ding, David Waller, Thierry Le Chevalier
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
Solange Peters, D. Ross Camidge, Alice T. Shaw, Shirish M. Gadgeel, Jin Seok Ahn, Dong‐Wan Kim, Sai‐Hong Ignatius Ou, M. Pérol, Rafał Dziadziuszko, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Sophie Golding, Bogdana Balas, Johannes Noé, Peter N. Morcos, Tony Mok
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres, Alexander Drilon, Amélie Lusque, Laurent Mhanna, Alexis B. Cortot, Laura Mezquita, Alesha A. Thai, Céline Mascaux, S. Couraud, Rémi Veillon, Michel M. van den Heuvel, Joel W. Neal, Nir Peled, Martin Früh, Terry L. Ng, V. Gounant, Sanjay Popat, Joachim Diebold, Joshua K. Sabari, Viola W. Zhu, Sacha I. Rothschild, Paolo Bironzo, Alex Martínez‐Martí, Alessandra Curioni‐Fontecedro, Rafael Rosell, Mickaël Lattuca-Truc, Marcel Wiesweg, Benjamin Besse, Benjamin Solomon, Fabrice Barlési, Robert D. Schouten, Heather A. Wakelee, D. Ross Camidge, Gérard Zalcman, Silvia Novello, Sai‐Hong Ignatius Ou, Julie Milia, Oliver Gautschi
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang, Jae Cheol Lee, Luping Lin, Victor Olivas, Valerie Au, Thomas LaFramboise, Mohamed Abdel-Rahman, Xiaoqi Wang, Alan D. Levine, Jin Kyung Rho, Yun Jung Choi, Chang‐Min Choi, Sang-We Kim, Se Jin Jang, Young Soo Park, Woo Sung Kim, Dae Ho Lee, Jung‐Shin Lee, Vincent A. Miller, Maria E. Arcila, Marc Ladanyi, Philicia Moonsamy, Charles L. Sawyers, Titus J. Boggon, C. Patrick, Carlota Costa, Miquel Tarón, Rafael Rosell, Balázs Halmos, Trever G. Bivona
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi‐Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, R. Linke, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Eric Sbar, Tao Wang, Jane Liang White, Sashi Nadanaciva, Rickard Sandin, Tony Mok
How much of the research on Instituto Oncológico Dr. Rosell is open access?
ScholarIQopen access share
50%OPEN ACCESS